APPLICATIONS PUBLISHED 28 JULY 2004
Published: 1-Feb-2005
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Oral compsns
Ineos Silicas 1439814*
Compsn containing feverfew extract and use thereof
Johnson & Johnson Consumer Co 1439817*
Chewable tablet containing lysine
Boehringer Ingelheim 1439818*
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
DepoMed 1439819*
Methods and dosage forms for improving the bioavailability of therapeutic agents
Labopharm; Labopharm Europe; Labopharm (Barbados) 1439820*
Pro-micelle pharmaceutical compsns
Imi Biomed 1439821*
Metallothioneine-containing liposomes
Universitat Autonoma de Barcelona 1439822*
Pharmaceutical formulations comprising (R)-bicalutamide
AstraZeneca 1439823*
Three-dimensional suspension printing of dosage forms
Therics 1439824*
Methods of treatment using a gastric retained gabapentin dosage
DepoMed 1439825*
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
DepoMed 1439826*
Inhalation of vapour of therapeutic substances
GW Pharma 1439827*
Veterinary florfenicol formulation that is syringeable under cold conditions
Phoenix Scientific 1439828*
Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
Gruenenthal 1439829*
Pharmaceutical compsn of 2-(4-isobutylphenyl)propionic acid
Cumberland Pharmaceuticals 1439830*
Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
New Technology Research 1439831*
Method of treating acne vulgaris using avermectin compound
Parks, L Dean 1439832*
Combination of liponic acid and glutamine in food and pharmaceutical products
BASF 1439833*
Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPS)
Applied Research Systems 1439834*
Medical compsns for intravesical treatment of bladder cancer
Spectrum Pharmaceuticals 1439835*
Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
Pfizer Products 1439836*
Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
Applied Research Systems 1439837*
Macrolides containing pharmaceutical compsns
Novartis 1439838*
A combination comprising comnbretastatin and anticancer agents
Aventis Pharma 1439839*
Monobactam antibacterial compounds and methods of use thereof
Chiron Corp 1439840*
Androgen receptor modulators and methods of use thereof
Merck 1439841*
Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
National Jewish Medical and Research Centre; Aeolus Pharmaceuticals; Piganelli, Jon; Haskins, Katherine; Flores, Sonia; Gill, Ronald 1439842*
Tetracycline derivatives and methods of use thereof
Tetragenex Pharmaceuticals 1439843*
Pharmaceutical preparation comprising a growth factor and/or a cytokine and an antiseptic biguanide
Fresenius Kabi Deutschland 1439844*
Inactivation of papillomavirus
McCloskey, Jenny Colleen 1439845*
Storage-stable human fibrinogen solutions
Woolverton, Christopher 1439846*
Method and compsn for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
Xu, Rongxiang 1439847*
L-methionine as a stabiliser for NESP/EPO in HSA-free formulations
Kirin-Amgen 1439848*
Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
Vanderbilt University 1439849*
Soluble proteins that inhibit cytokine signal transduction pathways
Eli Lilly 1439850*
Methods and compsns for the treatment and diagnosis of cellular proliferation disorders using 54394
Millennium Pharmaceuticals 1439851*
Peptides and related compounds having thrombopoietic activity
Amgen 1439852*
Means for inhibition of lentiviruses
Will, Hans 1439853*
Conformationally constrained parathyroid hormone (PTH) analogues
The General Hospital Corporation 1439854*
Compsn and method for minimising or avoiding adverse effects of vesicants
Quick Med Technologies 1439855*
Recombinant rabies vaccine and methods for preparation and use
Thomas Jefferson University 1439856*
Use of bispecific antibodies to regulate immune responses
Schering Corp 1439857*
Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compsns
Degussa 1439858*
An antineoplastic dendritic polymer drug delivery system
The Dow Chemical Company 1439859*
Magnetic nanodispersion comprising cyclodextrines and a method for the production thereof
Berlin Heart AG 1439860*
Methods and uses for kits in selecting approaches for treating cancer
The University of Chicago 1439861*
Methods and compsns for the treatment and diagnosis of pain disorders using 9805
Millennium Pharmaceuticals 1439862*
MNK kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
DeveloGen AG 1439863*
